Home » Reuters Creates The Outpartnering Registry
Reuters Creates The Outpartnering Registry
PharmaManufacturing.com
07/13/2010
Thomson Reuters announced recently that it has launched The Outpartnering Registry, an innovative resource designed to change the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around the world.
The Outpartnering Registry is available free to all organizations with drugs in development. It enables authorized users to share essential information about their company and drug pipeline with potential partners. Ninety percent of the world's top 50 pharmaceutical companies will have access to information in the registry via Thomson Pharma Partnering, the leading source of pipeline intelligence.
The Outpartnering Registry allows organizations to:
- Indicate which of their programs and drugs are available for partnering and, optionally, what type of partnership they are seeking in which regions of the world.
- Add and update partnering contacts together with links to LinkedIn profiles.
- Display attendance at partnering conferences and increase networking opportunities.
"Pharma companies need new and innovative ways to share the financial risk of developing drugs," said Mark Gordon, director of product strategy at Thomson Reuters. "This new initiative benefits both drug innovators, who can easily update their partnering information online, as well as in-licensors, who can quickly find assets available for partnering."
"The Outpartnering Registry from Thomson Reuters will make it easier for us to market products for our clients," said Damon Bowe, consultant at New Orleans BioInnovation Center. "The industry has expressed the need for this registry and it is an effective way for us to market inventions and to create partnerships between academia and industry."
For more information about The Outpartnering Registry, please visit: http://go.thomsonreuters.com/outpartnering
For more information about Thomson Pharma Partnering, please visit: http://go.thomsonreuters.com/partnering
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers

Print page